This page is formatted for easy printing, click here to return to the main post.
Morpholinos for DMD
jonmoulton
Posted 12/22/2009 9:55:07 AM
|
AVI Biopharma is reporting that their Morpholino drug for Duchenne muscular dystrophy is successfully triggering dose-dependent exon-skipping in the early low-dose phase of their systemic trial. Doses of 2 and 4 mg/Kg induced exon skipping and higher dosing is ongoing.
http://finance.yahoo.com/news/Systemic-Treatment-With-iw-679670786.html?x=0&.v=1
|
Back
|
Refer a Friend
Link To Us
Bookmark Us